Abstract
Interleukin-15 (IL-15) is a promising candidate for cancer immunotherapy due to its potent immune-activating effects. There are several IL-15 molecules currently in clinical trials but facing shortages of poor half-life, circulation instability, or complicated production and quality control processes. The aim of this study is to design a novel IL-15 superagonist to set out the above difficulties, and we constructed F4RLI consisting of the GS-linker spaced IgG4 Fc fragment, soluble IL-15 Rα (sIL-15Rα), and IL-15(N72D). Using a single plasmid transient transfection in HEK293E cells, the matured F4RLI was secreted in the form of homodimer and got purified by an easy step of protein A affinity chromatography. The F4RLI product can significantly stimulate the proliferation of human CD3+CD8+ T cells and NK cells in vitro. Meanwhile, F4RLI greatly extended the half-life and prolonged the exposure of IL-15 in mice nearly by 28- and 200-fold, respectively, in comparison with that of the IL-15 monomer. In vivo, F4RLI vastly expanded mouse splenic CD8+ T lymphocytes, illustrating its potential in tumor immunotherapy. Further studies showed that the combination of F4RLI with the immune checkpoint blocker atezolizumab played a synergistic effect in treating MC38 mouse tumor by increasing the percentage of CD8+ T cells in tumor tissue. Moreover, the combination therapy of F4RLI with the angiogenesis inhibitor bevacizumab resulted in significant tumor growth suppression in a xenograft human HT-29 mouse model. Overall, our results demonstrate a homodimeric IL-15 superagonist F4RLI with advances in manufacturing processes and biopharmaceutical applications for cancer immunotherapy.
Key points
• The homodimeric structure of F4RLI facilitates its easy production processes and quality control.
• The fusion with Fc and sIL-15Rα extends the plasma half-life of IL-15 by about 28-fold.
• F4RLI can play synergistic antitumor activity with the PD-1/PD-L1 checkpoint inhibitor or angiogenesis inhibitor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data generated or analyzed during this study are included in this published article and its supplementary information files.
References
Anton OM, Peterson ME, Hollander MJ, Dorward DW, Arora G, Traba J, Rajagopalan S, Snapp EL, Garcia KC, Waldmann TA, Long EO (2020) Trans-endocytosis of intact IL-15Ralpha-IL-15 complex from presenting cells into NK cells favors signaling for proliferation. Proc Natl Acad Sci U S A 117(1):522–531. https://doi.org/10.1073/pnas.1911678117
Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R, Chertova E, Rosenberg SA, Felber BK, Pavlakis GN (2012) Circulating IL-15 exists as heterodimeric complex with soluble IL-15R alpha in human and mouse serum. Blood 120(1):E1–E8. https://doi.org/10.1182/blood-2011-10-384362
Bessard A, Sole V, Bouchaud G, Quemener A, Jacques Y (2009) High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 8(9):2736–2745. https://doi.org/10.1158/1535-7163.MCT-09-0275
Cheever MAM (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222:357–368
Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS (2013) A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a cytokine working group (CWG) study. J Immunother 36(9):490–495. https://doi.org/10.1097/cji.0000000000000003
Fiore PF, Di Matteo S, Tumino N, Mariotti FR, Pietra G, Ottonello S, Negrini S, Bottazzi B, Moretta L, Mortier E, Azzarone B (2020) Interleukin-15 and cancer: some solved and many unsolved questions. J Immunother Cancer 8(2) https://doi.org/10.1136/jitc-2020-001428
Garcia JA, Mekhail T, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI (2011) Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int 107(4):562–570. https://doi.org/10.1111/j.1464-410X.2010.09573.x
Han KP, Zhu X, Liu B, Jeng E, Kong L, Yovandich JL, Vyas VV, Marcus WD, Chavaillaz PA, Romero CA, Rhode PR, Wong HC (2011) IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56(3):804–810. https://doi.org/10.1016/j.cyto.2011.09.028
Hangasky JA, Waldmann TA, Santi DV (2020) Interleukin 15 pharmacokinetics and consumption by a dynamic cytokine sink. Front Immunol 11:1813. https://doi.org/10.3389/fimmu.2020.01813
Huang XQ, Hamilton MJ, Li CL, Schmidt C, Ellem KA (2006) An extraordinarily high level of IL-15 expression by a cell line transduced with a modified BMGneo vector displays hypoxic upregulation. Mol Biotechnol 33(1):49–56. https://doi.org/10.1385/MB:33:1:49
Lee S, Margolin K (2011) Cytokines in Cancer Immunotherapy Cancers 3(4):3856–3893. https://doi.org/10.3390/cancers3043856
Ma A, Boone DL, Lodolce JP (2000) The pleiotropic functions of interleukin 15: not so interleukin 2-like after all. J Exp Med 191(5):753–755. https://doi.org/10.1084/jem.191.5.753
Ma A, Koka R, Burkett P (2006) Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 24:657–679. https://doi.org/10.1146/annurev.immunol.24.021605.090727
Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y (2000) IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A 97(21):11445–11450. https://doi.org/10.1073/pnas.200363097
Meric-Bernstam F, Larkin J, Tabernero J, Bonini C (2021) Enhancing anti-tumour efficacy with immunotherapy combinations. The Lancet 397(10278):1010–1022. https://doi.org/10.1016/s0140-6736(20)32598-8
Mortier E, Quéméner A, Vusio P, Lorenzen I, Boublik Y, Grötzinger J, Plet A, Jacques Y (2006) Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ. J Bio Chem 281(3):1612–1619. https://doi.org/10.1074/jbc.M508624200
Murakami J, Wu L, Kohno M, Chan ML, Zhao Y, Yun Z, Cho BCJ, de Perrot M (2021) Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma. Sci Transl Med. 13(589):eabd9882. https://doi.org/10.1126/scitranslmed.abd9882
Patidar M, Yadav N, Dalai SK (2016) Interleukin 15: a key cytokine for immunotherapy. Cytokine Growth Factor Rev 31:49–59. https://doi.org/10.1016/j.cytogfr.2016.06.001
Rosen LS, Jacobs IA, Burkes RL (2017) Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol 12(5):599–610. https://doi.org/10.1007/s11523-017-0518-1
Sakaguchi S (2011) Regulatory T cells: history and perspective. In: Kassiotis G, Liston A (eds) Regulatory T cells: methods and protocols. Methods Mol Biol, vol 707. Humana Press Inc, 999 Riverview Dr, Ste 208, Totowa, Nj 07512–1165 USA, pp 3–17
Shi SW, Chen HH, Jiang H, Xie YQ, Zhang L, Li NH, Zhu CC, Chen JS, Luo H, Wang JX, Feng L, Lu HL, Zhu JW (2017) A novel self-cleavable tag Zbasic-Delta I-CM and its application in the soluble expression of recombinant human interleukin-15 in Escherichia coli. Appl Microbiol Biotechnol 101(3):1133–1142. https://doi.org/10.1007/s00253-016-7848-2
Sneller MC, Kopp WC, Engelke KJ, Yovandich JL, Creekmore SP, Waldmann TA, Lane HC (2011) IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8(+) T effector memory population in peripheral blood. Blood 118(26):6845–6848. https://doi.org/10.1182/blood-2011-09-377804
Sun W, Lai YX, Li HB, Nie T, Kuang Y, Tang XF, Li K, Dunbar PR, Xu AM, Li P, Wu DH (2016) High level expression and purification of active recombinant human interleukin-15 in Pichia pastoris. J Immunol Methods 428:50–57. https://doi.org/10.1016/j.jim.2015.12.002
Thaysen-Andersen M, Chertova E, Bergamaschi C, Moh ES, Chertov O, Roser J, Sowder R, Bear J, Lifson J, Packer NH, Felber BK, Pavlakis GN (2016) Recombinant human heterodimeric IL-15 complex displays extensive and reproducible N- and O-linked glycosylation. Glycoconj J 33(3):417–433. https://doi.org/10.1007/s10719-015-9627-1
Waldmann TA, Miljkovic MD, Conlon KC (2020) Interleukin-15 (dys)regulation of lymphoid homeostasis: implications for therapy of autoimmunity and cancer. J Exp Med 217(1) https://doi.org/10.1084/jem.20191062
Wang Y, Wang M, Wu HX, Xu RH (2021) Advancing to the era of cancer immunotherapy. Cancer Commun (lond) 41(9):803–829. https://doi.org/10.1002/cac2.12178
Wei X, Orchardson M, Gracie JA, Leung BP, Gao B, Guan H, Niedbala W, Paterson GK, McInnes IB, Liew FY (2001) The Sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo. J Immunol 167(1):277–282. https://doi.org/10.4049/jimmunol.167.1.277
Weng NP, Liu KB, Catalfamo M, Li Y, Henkart PA (2002) IL-15 is a growth factor and an activator of CD8 memory T cells. In: Aujame L, Burdin N, Dodet B, Vicari M (eds) Microarrays, Immune Responses and Vaccines. Ann N Y Acad Sci, vol 975. New York Acad Sciences, New York, pp 46–56
Wong HC, Jeng EK, Rhode PR (2013) The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity. OncoImmunology 2(11):3. https://doi.org/10.4161/onci.26442
Xiao Q, Wu J, Wang WJ, Chen S, Zheng Y, Yu X, Meeth K, Sahraei M, Bothwell ALM, Chen L, Bosenberg M, Chen J, Sexl V, Sun L, Li L, Tang W, Wu D (2018) DKK2 imparts tumor immunity evasion through beta-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24(3):262–270. https://doi.org/10.1038/nm.4496
Xu H, Shi M, Shao C, Li H, Wu J, Yu Y, Fang F, Guo Y, Xiao W (2021) Development of IL-15/IL-15Ralpha sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives. Microb Cell Fact 20(1):115. https://doi.org/10.1186/s12934-021-01605-3
Xu WX, Jones M, Liu B, Zhu XY, Johnson CB, Edwards AC, Kong L, Jeng EK, Han KP, Marcus WD, Rubinstein MP, Rhode PR, Wong HC (2013) Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alpha Su/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res 73(10):3075–3086. https://doi.org/10.1158/0008-5472.Can-12-2357
Yang J, Yan J, Liu BR (2018) Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol 9:9. https://doi.org/10.3389/fimmu.2018.00978
Zhao M, Luo M, Xie Y, Jiang H, Cagliero C, Li N, Ye H, Wu M, Hao S, Sun T, Yang H, Zhang M, Lin T, Lu H, Zhu J (2019) Development of a recombinant human IL-15.sIL-15Ralpha/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model. Biomed Pharmacother 112:108677. https://doi.org/10.1016/j.biopha.2019.108677
Zhu X, Marcus WD, Xu W, Lee HI, Han K, Egan JO, Yovandich JL, Rhode PR, Wong HC (2009) Novel human interleukin-15 agonists. J Immunol 183(6):3598–3607. https://doi.org/10.4049/jimmunol.0901244
Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Antsaklis A, Dimopoulos MA, Bamias A (2012) VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int J Cancer 130(4):857–864. https://doi.org/10.1002/ijc.26094
Funding
This work was supported by the Science and Technology Commission of Shanghai Municipality (No. 21S11906300 to Lu H.).
Author information
Authors and Affiliations
Contributions
LL: conceived of or designed study; performed research; analyzed data; wrote the paper. HW: performed research; contributed new methods or models. WS: performed research; contributed new methods or models. YW: performed research. WZ: analyzed data. ZL: analyzed data. XC: performed research. CZ: resources. WK: resources. WL: resources. JZ: resources. HL: conceived of or designed study; funding acquisition; wrote and edited the paper. All the authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethical approval
All animal experiments were approved by the Animal Care and Use Committee of Shanghai Jiao Tong University.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Lv, L., Wang, H., Shi, W. et al. A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities. Appl Microbiol Biotechnol 106, 7039–7050 (2022). https://doi.org/10.1007/s00253-022-12209-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-022-12209-1